發(fā)布時(shí)間：2018-12-27 08:42

【摘要】：目的：探討宮頸鱗癌(CSCC)組織中表皮生長(zhǎng)因子受體(EGFR)、原癌基因c-jun、c-fos表達(dá)與臨床特征及近期療效的關(guān)系,評(píng)估其在CSCC進(jìn)展和近期療效中的價(jià)值。方法：對(duì)60例CSCC組織標(biāo)本采用熒光原位雜交(FISH)技術(shù)檢測(cè)EGFR基因擴(kuò)增及基因拷貝數(shù)；免疫組織化學(xué)法檢測(cè)EGFR、c-jun、c-fos蛋白表達(dá)。采用卡方或確切概率、非參數(shù)Spearman等級(jí)相關(guān)、多因素Logistic回歸等統(tǒng)計(jì)分析方法。結(jié)果：4種EGFR基因雜交模式所占比例分別為二倍體32.2%、三倍體25.4%、多倍體30.5%、基因擴(kuò)增率11.9%；EGFR、c-jun、c-fos蛋白陽性表達(dá)率分別為70.0%、76.7%、68.3%；EGFR、c-jun、c-fos蛋白表達(dá)均與腫瘤分化程度、淋巴結(jié)轉(zhuǎn)移有關(guān)(P0.05),EGFR蛋白表達(dá)還與臨床分期有關(guān)(P=0.006),Spearman等級(jí)相關(guān)分析顯示：EGFR蛋白表達(dá)水平與基因拷貝數(shù)增加呈顯著正相關(guān)(r=0.622,P=0.000),c-jun、c-fos蛋白表達(dá)與臨床分期呈正相關(guān)(r=0.293,P=0.023；r=0.296,P=0.022),EGFR與c-jun、c-fos蛋白表達(dá)水平呈正相關(guān)(r=0.422,P=0.001:r=0.509,P=0.000),EGFR、c-jun、c-fos蛋白表達(dá)對(duì)客觀有效率RR無明顯影響(P0.05)。結(jié)論：EGFR、c-jun、c-fos表達(dá)可能為CSCC高危進(jìn)展、轉(zhuǎn)移和預(yù)后的參考指標(biāo)；EGFR、c-jun、c-fos表達(dá)均不是影響CSCC近期療效的獨(dú)立因素；c-jun、c-fos在EGFR介導(dǎo)的信號(hào)傳導(dǎo)通路中可能發(fā)揮正性調(diào)節(jié)作用；聯(lián)合檢測(cè)EGFR、c-jun、c-fos為CSCC的診斷、個(gè)體化療法提供理論依據(jù)。
[Abstract]:Objective: to investigate the relationship between the expression of proto-epidermal growth factor receptor (EGFR),) oncogene c-jun c-fos and its clinical features and short-term efficacy in cervical squamous cell carcinoma (CSCC), and to evaluate the value of c-junc-fos expression in the progression and short-term curative effect of CSCC. Methods: the amplification and copy number of EGFR gene were detected by fluorescence in situ hybridization (FISH) in 60 cases of CSCC and the expression of EGFR,c-jun,c-fos protein was detected by immunohistochemistry. Statistical analysis methods such as chi-square or exact probability, nonparametric Spearman rank correlation and multivariate Logistic regression were used. Results: the proportion of the four EGFR gene hybridization patterns was 32. 2 diploid, 25. 4 triploid, 35. 5 polyploid and 11. 9% gene amplification. The positive expression rates of EGFR,c-jun,c-fos protein were 70.0% and 76.78.3%, respectively. The expression of EGFR,c-jun,c-fos protein was related to the degree of tumor differentiation and lymph node metastasis (P0.05). The expression of), EGFR protein was also related to clinical stage (P0. 006). Spearman grade correlation analysis showed that there was a significant positive correlation between the expression level of EGFR protein and the increase of gene copy number (r = 0.622), while the expression of c-junn c-fos protein was positively correlated with the clinical stage (r = 0.293). There was a positive correlation between the expression of c-junn c-fos protein and the expression level of c-junn c-fos protein (0.296), EGFR). The expression of EGFR,c-jun,c-fos protein had no significant effect on the objective effective RR (P0.05). Conclusion: the expression of EGFR,c-jun,c-fos may be a reference index for the high risk progression, metastasis and prognosis of CSCC, and the expression of EGFR,c-jun,c-fos is not an independent factor affecting the short-term curative effect of CSCC. C-junn c-fos may play a positive role in the signal transduction pathway mediated by EGFR, and the combined detection of EGFR,c-jun,c-fos may provide theoretical basis for the diagnosis of CSCC and individualized therapy.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 馬玲;劉莉;張濤;單莉;;晚期NSCLC患者血清EGFR基因突變狀態(tài)的測(cè)定及意義[J];中國(guó)肺癌雜志;2013年06期

2 包蕾;李素紅;王全紅;;宮頸鱗癌中HER2、EGFR的表達(dá)及臨床意義[J];中國(guó)醫(yī)療前沿;2012年03期

3 蔣騫;譚榜憲;周業(yè)琴;馬代遠(yuǎn);任濤;;178例宮頸癌患者預(yù)后因素的臨床研究[J];醫(yī)學(xué)理論與實(shí)踐;2012年13期

4 李青;紀(jì)捷;吳王飛;周曉軍;;宮頸鱗狀上皮病變中EGFR蛋白表達(dá)及基因擴(kuò)增的臨床意義[J];診斷病理學(xué)雜志;2010年06期

5 馮淑瑜;鄧玲紅;康佳麗;夏薇;張彥娜;李莉平;程海燕;孫晉瑞;孫學(xué)明;;表皮生長(zhǎng)因子受體表達(dá)與高危型人乳頭狀瘤病毒載量在宮頸癌及癌前病變中的相關(guān)性[J];中國(guó)婦幼保健;2010年30期

6 趙麗霞;張晨;耿文;;新疆地區(qū)51226例不同民族婦女宮頸病變檢查結(jié)果分析[J];中國(guó)預(yù)防醫(yī)學(xué)雜志;2012年07期

7 鐘麗;傅芬;蔡勇;;人宮頸癌中EGFR基因突變的檢測(cè)[J];中國(guó)腫瘤生物治療雜志;2010年06期

8 周建欣;江瑞范;張立新;李瑞亭;;年輕婦女宮頸癌臨床分析[J];中國(guó)實(shí)用醫(yī)藥;2010年11期

9 Apaporn Menakongka;Tuangporn Suthiphongchai;;Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion[J];World Journal of Gastroenterology;2010年06期

，

本文編號(hào)：2392796